Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy
Giovanna Garufi(Agostino Gemelli University Polyclinic), Emilio Bria(Università Cattolica del Sacro Cuore), Federica Miglietta(University of Padua), Isabella Sperduti(Istituti di Ricovero e Cura a Carattere Scientifico), Sara Pilotto(University of Verona), Luisa Carbognin(Agostino Gemelli University Polyclinic), Gianluca Franceschini(Agostino Gemelli University Polyclinic), Michèle Milella(National Cancer Institute), Antonio Franco(Università Cattolica del Sacro Cuore), Giovanni Scambia(Agostino Gemelli University Polyclinic), Ida Paris(Agostino Gemelli University Polyclinic), Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Alessandra Fabi(Agostino Gemelli University Polyclinic), Giampaolo Tortora(University of Naples Federico II), Lorenzo Gerratana(National Cancer Institute), Roberta Mazzeo(University of Udine), Antonella Palazzo(Agostino Gemelli University Polyclinic), Maria Vittoria Dieci(Istituto Oncologico Veneto), Armando Orlandi(Agostino Gemelli University Polyclinic), Elena Fiorio(University of Verona), Fabio Puglisi(University of Udine)
Cited by 11
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k